MedTrace Logo

Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder

NCT02384369 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2016-04-18

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled study of SNC-102 in adult subjects with cPTSD, added to pre-existing treatment that includes prazosin with or without other psychotropic drugs.

Subjects will be treated with SNC-102 tablets or matching placebo on a BID basis for 8 weeks. Subjects will be evaluated for the symptoms of combat-related posttraumatic stress disorder (cPTSD) as measured by the Clinician Administered PTSD Scale (CAPS-5), compared with the response to placebo.

Conditions

  • Post-Traumatic Stress Disorders
  • Posttraumatic Stress Disorders
  • Stress Disorders, Post-Traumatic
  • Post-Traumatic Stress Disorders, Combat-related

Interventions

DRUG

SNC-102 sustained release tablet

Sustained release oral tablet of SNC-102

Sponsors & Collaborators

  • Synchroneuron Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-06-30
Completion
2017-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02384369 on ClinicalTrials.gov